Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Di Weng

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancer Cell International|April 2, 2021
Immunological significance of prognostic alternative splicing signature in hepatocellular carcinomaQianhui Xu, Hao Xu, Rongshan Deng, et al.
Cancer Cell International|August 25, 2021
Correction to: Immunological significance of prognostic alternative splicing signature in hepatocellular carcinomaQianhui Xu, Hao Xu, Rongshan Deng, et al.
Translational Lung Cancer Research|November 7, 2024
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired <i>BRAF</i> V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced <i>EGFR</i>-mutated non-small cell lung cancer patientsCheng-Di Weng, Ke-Jun Liu, Shi Jin, et al.
Therapeutic Advances in Medical Oncology|February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world studyJun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
Discover Oncology|May 27, 2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skippingJiao Yang, Cheng-Di Weng, Han-Min Wang, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancer Cell International|April 2, 2021
Immunological significance of prognostic alternative splicing signature in hepatocellular carcinomaQianhui Xu, Hao Xu, Rongshan Deng, et al.
Cancer Cell International|August 25, 2021
Correction to: Immunological significance of prognostic alternative splicing signature in hepatocellular carcinomaQianhui Xu, Hao Xu, Rongshan Deng, et al.
Translational Lung Cancer Research|November 7, 2024
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired <i>BRAF</i> V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced <i>EGFR</i>-mutated non-small cell lung cancer patientsCheng-Di Weng, Ke-Jun Liu, Shi Jin, et al.
Therapeutic Advances in Medical Oncology|February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world studyJun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
Discover Oncology|May 27, 2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skippingJiao Yang, Cheng-Di Weng, Han-Min Wang, et al.
Pageof 4